+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Cansidas"

Cansidas - API Insight, 2022 - Product Thumbnail Image

Cansidas - API Insight, 2022

  • Drug Pipelines
  • January 2022
  • 30 Pages
  • Global
From
Cansidas- Drug Insight, 2019 - Product Thumbnail Image

Cansidas- Drug Insight, 2019

  • Report
  • January 2019
  • 35 Pages
  • Global
From
  • 2 Results (Page 1 of 1)
Loading Indicator

The Cansidas market is a segment of the infectious diseases drugs market that focuses on the development and commercialization of treatments for bacterial, viral, and fungal infections. This market is driven by the increasing prevalence of infectious diseases, the emergence of drug-resistant strains, and the need for new treatments. Companies in this market are developing novel therapies, such as monoclonal antibodies, vaccines, and antiviral drugs, to address the growing global health burden. The Cansidas market is highly competitive, with a number of large pharmaceutical companies and biotechnology firms vying for market share. Companies in this market include Pfizer, Merck, GlaxoSmithKline, Johnson & Johnson, Novartis, Sanofi, and AstraZeneca. These companies are investing heavily in research and development to develop new treatments and expand their product portfolios. Show Less Read more